Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:

NCT ID: NCT04609891 Completed - Thrombocytopenia Clinical Trials

Avatrombopag on the Treatment of Thrombocytopenia Induced by Chemotherapy of Malignant Tumors

Start date: May 26, 2020
Phase: N/A
Study type: Interventional

To observe the clinical efficacy and safety of avatrombopag for chemotherapy-induced thrombocytopenia in patients with malignant tumors.

NCT ID: NCT04350164 Completed - Clinical trials for Wiskott-Aldrich Syndrome

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Start date: April 1, 2012
Phase:
Study type: Observational

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

NCT ID: NCT04348799 Completed - Clinical trials for Bronchopulmonary Dysplasia

Thrombocytopoiesis and Platelet Homeostasis in Infants With Bronchoplumonary Dysplasia

BPD
Start date: January 1, 2019
Phase:
Study type: Observational

To investigate the relationship between bronchopulmonary dysplasia and thrombocytopenia.

NCT ID: NCT04346654 Completed - Clinical trials for Immune Thrombocytopenia (ITP)

A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITP

XPAG-ITP
Start date: October 9, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the ability of eltrombopag in combination with a short course of high-dose dexamethasone to induce sustained response off treatment in patients with newly-diagnosed ITP versus 1-3 cycles of dexamethasone monotherapy. The unmet clinical need and the potential for eltrombopag when added to steroids to improve the treatment outcome and the potential to induce sustained response off treatment serve as the basis for clinical investigation of eltrombopag in first-line ITP.

NCT ID: NCT04217148 Completed - Clinical trials for Immune Thrombocytopenia

The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to compare the efficacy and safety of ATRA plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

NCT ID: NCT04188379 Completed - Clinical trials for Primary Immune Thrombocytopenia

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

ADVANCE
Start date: December 16, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in participants with primary ITP.

NCT ID: NCT04159064 Completed - Clinical trials for Coagulation Disorder

Impact of Cardiac Surgery With a Minimal Invasive Extracorporeal Circuit οn Coagulation: Data From Point of Care Devices

Start date: December 1, 2018
Phase:
Study type: Observational

This study includes patients undergoing elective cardiac surgery on MiECC. Coagulation status is assessed with ROTEM (TEM International GmbH, Munich, Germany) and Platelet function with impedance aggregometry using the ROTEM-Platelet (TEM International GmbH, Munich, Germany).

NCT ID: NCT04155775 Completed - Thrombocytopenia Clinical Trials

Effects of a Platelet Transfusion Best Practices Alert

Start date: May 9, 2019
Phase: N/A
Study type: Interventional

This study is to determine the effectiveness of a computerized clinical decision support tool (Best Practice Alert - BPA) in reducing unnecessary platelet transfusions based on guidelines published by national transfusion societies such as the AABB (formerly American Association of Blood Banks).

NCT ID: NCT04089267 Completed - ITP Clinical Trials

Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)

Start date: December 2016
Phase: Phase 4
Study type: Interventional

This is a review of the efficacy and safety of different recombinant human thrombopoietin (rhTPO) regimens in the treatment of patients with primary immune thrombocytopenia (ITP).

NCT ID: NCT04083014 Completed - Clinical trials for Autoimmune Hemolytic Anemia

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

RRAIHA01
Start date: August 20, 2019
Phase: Phase 2
Study type: Interventional

Patients of relapsed and refractory warm autoimmune hemolytic anemia or EVANS syndrome aged 18 to 80 will be included in this study. The treatment regimen is a single dose anti-CD20 antibody (500mg) combined with bortezomib (1.3mg/m2 twice a week for two weeks). The treatment course would be repeated three months later.